Thu, Aug 21, 2014, 3:18 AM EDT - U.S. Markets open in 6 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • dragan7777777777 dragan7777777777 Dec 10, 2010 5:36 AM Flag

    Today....

    Friday, December 10

    Abstract: P2-09-05


    Poster Session 2 (Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors): "Risk group selection in primary breast cancer according to ASCO-recommended biomarkers of Oncotype DX and uPA-PAI-1: First experience from prospective multicenter WSG Plan B trial"
    Lead Author: T. Degenhardt, MD, West German Study Group
    Location: Exhibit Halls A-B
    Time: 7 a.m. – 9 a.m.


    Abstract: P2-09-06

    Poster Session 2 (Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors): "Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score® in clinical practice"

    Lead Author: John Hornberger, MD, MS, CEO & President, Cedar Associates LLC and Adjunct Professor of Medicine, Stanford University
    Location: Exhibit Halls A-B
    Time: 7 a.m. – 9 a.m.

    Abstract: S4-9

    General Session 4: "Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the Recurrence Score and a new measure that integrates clinical and pathologic factors with the Recurrence Score"

    Presenter: Gong Tang, PhD, Assistant Professor of Biostatistics, University of Pittsburgh and Statistician, the NSABP Biostatistical Center
    Location: Exhibit Hall D
    Time: 3:15 p.m. – 5:30 p.m.


    Abstract: P3-10-01

    Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Quantitative gene expression analysis in a large cohort of estrogen-receptor positive breast cancers: Characterization of the tumor profiles in younger patients (<40 yrs) and in older patients (>70 yrs)"

    Lead Author: Steven Shak, MD, Genomic Health
    Location: Exhibit Halls A-B
    Time: 5:30 p.m. - 7:30 p.m.


    Abstract: P3-10-12

    Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): Pilot Phase of the Randomized Plan B Trial: Prospective Comparison of Molecular Classification, Oncotype DX and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer

    Lead Author: Oleg Gluz, MD, West German Study Group
    Location: Exhibit Halls A-B
    Time: 5:30 p.m. - 7:30 p.m.


    Abstract: P3-10-13

    Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Prognostic value of genomic analysis after neoadjuvant chemotherapy for breast cancer"
    Lead Author: Erica L. Mayer, MD MPH, Staff Physician, Breast Oncology Center
    Dana-Farber Cancer Institute and Instructor in Medicine, Harvard Medical School

    Location: Exhibit Halls A-B
    Time: 5:30 p.m. - 7:30 p.m.

    Abstract: P3-10-15

    Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Quantitative gene expression by RT-PCR in classic and variant forms of lobular carcinoma in estrogen receptor positive invasive breast cancer"
    Lead Author: Joseph M. Anderson, MD, Genomic Health
    Location: Exhibit Halls A-B
    Time: 5:30 p.m. - 7:30 p.m.

 
GHDX
28.03+0.07(+0.25%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.